Recurrent Hepatitis C After Liver Transplantation Experience of the First 21 Patients Treated in Lausanne

Détails

ID Serval
serval:BIB_6B134F00BF06
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Recurrent Hepatitis C After Liver Transplantation Experience of the First 21 Patients Treated in Lausanne
Titre de la conférence
Annual Meeting of the Swiss Society of Gastroenterology, Swiss Society for Visceral, Surgery Swiss Association for the Study of the Liver, Swiss Association of Clinical Nutrition
Auteur(s)
Antonino Anca T., Fontana Massimiliano, Giostra Emiliano, Pascual Manuel, Moradpour Darius
Adresse
Interlaken, Switzerland, September 23-24, 2010
ISBN
1424-7860
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
140
Série
Swiss Medical Weekly
Pages
20S
Langue
anglais
Notes
Meeting Abstract
Résumé
BACKGROUND AND AIM: Recurrent hepatitis C is a major cause of morbidity and mortality after liver transplantation (LT), and optimal treatment algorithms have yet to be defined. Here, we present our experience of the first 21 patients with recurrent hepatitis C treated in Lausanne.
PATIENTS AND METHODS: Twenty-one patients with histologyproven recurrent hepatitis C after LT were treated since 2003. Treatment was initiated with pegylated interferon-α2a 135 μg per week and ribavirin 400 mg per day in the majority of patients, and subsequent doses were adapted individually based on on-treatment virological responses and clinical and/or biochemical side effects.
RESULTS: On an intention-to-treat basis, sustained virological response (SVR) was achieved in 12/21 (57%) patients (5/11 [45%], 2/3 [67%], 4/5 [80%] and 1/2 [50%] of patients infected with genotypes 1, 2, 3 and 4, respectively). Two patients experienced relapse and 6 did not respond to treatment (NR). Treatment duration ranged from 24 to 90 weeks. It was stopped prematurely due to adverse events in 5/21 (24%) patients (with SVR achieved in 2 patients, NR in 2 patients, and death of one patient awaiting re-transplantation). Of note, SVR was achieved in a patient with combined liver and kidney transplantation. Importantly, SVR was achieved in some patients despite the lack of an early virological response or HCV RNA negativity at week 24. Darbepoetin α and filgrastim were used in 33% and 14%, respectively.
CONCLUSION: Individually adapted treatment of recurrent hepatitis C can achieve SVR in a substantial proportion of LT patients. Conventional stopping rules do not apply in this setting so that prolonged therapy may be useful in selected patients.
Web of science
Création de la notice
04/11/2010 15:19
Dernière modification de la notice
20/08/2019 14:25
Données d'usage